Brian J. Druker, the Father of Gleevec

It was Druker’s lab that did the basic work showing that STI571 [Gleevec] had potential, and Druker who talked the pharmaceutical giant Novartis into testing the compound on patients. His 1996 Nature Medicine article reporting on the performance of STI571 in the laboratory has been cited more than 400 times